CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Australia's CSL...

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Australia's CSL said on Monday it had entered ​into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development ​funding.